New investment highlights the potential impact of Abselion’s technology for life sciences research and bioprocess development.
Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing, to bring its award-winning Amperia system to market.
The cutting-edge benchtop instrument allows scientists to easily quantify antibodies, AAVs and other proteins directly from crude samples, in as little as one minute. This provides critical data on the spot, enhancing efficiency and accuracy in life sciences research and bioprocessing.
The funding round was led by M Ventures (the strategic corporate venture capital arm of science and technology company Merck), and includes new investors BioProcess 360 Partners and Untitled Ventures. BGF also contributed to the funding round, alongside R42 and other existing investors.
“We are delighted to have the support of our investment partners to advance our mission to provide scientists with critical, real-time data at the point of need. The Amperia RED technology delivers the accuracy, speed and agility required for insights that enable confident decision making, driving bioprocess optimisation and innovation.”
Ruizhi Wang
CEO of Abselion
Abselion will use the funds to drive the commercialisation and expand the capabilities of its Amperia system. Built on proprietary Redox Electrochemical Detection (RED) technology, Amperia brings a ground-breaking approach to biologics and viral-vector quantification — for confident, convenient and cost-effective automated, at-line measurement that’s accessible to all laboratories and process environments.
“We’re proud to continue our support for Abselion, as it pioneers a new standard in bioprocess analytics. The team’s dedication and innovation in addressing a critical challenge for the biopharma industry is impressive, and we’re thrilled to play a part in their ongoing journey.”
Luke Rajah
Investor at BGF
